All News
KL-6, Anti-Ku, anti-CENPB were assoc'd w/ #myositis &/or ILD in #lupus patients accdg to this study by Dr. T Cotton et al. This may help identify patients at risk for developing such.
@RheumNow #ACR21 abs0330 https://t.co/p0uxBOTLZm
sheila RHEUMarampa ( View Tweet)
RELIANCE interim data shows efficacy & safety of long-term CAN in FMF. This observational study is a good start, but offers questions regarding dosing of CAN in this patient population. Abs 0192 #ACR21 #RheumNow @RheumNow https://t.co/46o7AnUVj2 https://t.co/7oAPovbukl
Dr. Rachel Tate uptoTate ( View Tweet)
Pain in #spondyloarthritis is complex and multifactorial. Study of nearly 3000 patients, higher pain intensity was associated with working life impairment, spinal stiffness, education, gender, depression, anxiety and sleep @RheumNow, #ACR21 and Abst#0360 https://t.co/xEVI4L0Chw
Dr. Antoni Chan synovialjoints ( View Tweet)
#ACR21 Abst#0289: Predictive score for preclinical RA-ILD based on 4 identified RF:
⭐︎ ⚦ sex (OR 3.9)
⭐︎ MUC5B T-risk allele (OR 3.7)
⭐︎ mean DAS-28 (OR 2.0)
⭐︎ older age at RA onset (1.1)
Obtain HRCT if w/ above (Se ~87%)!
#ACRBest @Rheumnow https://t.co/KKRkQVY2pf https://t.co/wifiTi6vPq
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
RELIANCE interim data shows that long-term CAN is safe & effective in CAPS. Interestingly, investigators observed a trend toward updosing over standard dosing. Abs 0191 #ACR21 #RheumNow @RheumNow https://t.co/ik6dAEZjFf https://t.co/arqSEzuC6Q
Dr. Rachel Tate uptoTate ( View Tweet)
Great Debate on Voclosporin vs. Belimumab in Lupus Nephritis therapy.
Dr. Petri argues Belimumab has less potential AE including infections, cardiovascular risk, malignancy potential. No drug-drug interactions.
What would you choose?
#ACR21
#ACRBest
@RheumNow https://t.co/FywUp3zCj2
Robert B Chao, MD doctorRBC ( View Tweet)
Dr Patel @jeffsparks @zach_wallace_md comparative cohort study on CD-20 inhibitors and COVID. ⬆️ mortality, aHR 2.16 . Abstr#0085 #ACR21 @RheumNow https://t.co/wyfEBWurRi
Richard Conway RichardPAConway ( View Tweet)
@jhrheumatology Dr. Petri - if Lupus nephritis biopsy is very active start a dual therapy with MMF right away.
▶️ If not, continue to re-evaluate at 3 and 6 months for early combo therapy
#ACR21 Great Debate
@Rheumnow https://t.co/ctKdbWTMqy
Eric Dein ericdeinmd ( View Tweet)
How can we tell whether a patient already on rituximab will have an immunogenic response to Pfizer COVID-19 vaccination?
Better chance of response if:
- RA or SLE, not AAV or IIM
- high serum IgG pre-last RTX
- longer time since last RTX
Israeli data #ACR21 ABST0437 @RheumNow https://t.co/yyuFd0eDH6
David Liew drdavidliew ( View Tweet)
Dr McDermott @jeffsparks on risk factors for RA-bronchiectasis. Seropositivity, older age at RA onset, and lower BMI⬆️risk. Abstr#0288 #ACR21 @RheumNow https://t.co/7d2ZVWLzn6
Richard Conway RichardPAConway ( View Tweet)
#ACR21 Great Debate: Voclosporin vs Tacro?
⭐️Voclosporin has carbon bond extension, changing how voclosporin binds to calcineurin.
⭐️Consistent dose-response prevents need for drug monitoring
⭐️Increases potency and results in improved metabolic profile
@Rheumnow https://t.co/cY93st7754
Eric Dein ericdeinmd ( View Tweet)
This is an important slide showing how belimumab protected the GFR... ultimately the reason why we are treating #lupus nephritis patients - Prof Michelle Petri
@RheumNow #ACR21 #rheumatology
📌https://t.co/bO3ubqY2bf https://t.co/yuqwlKXDBH
Links:
sheila RHEUMarampa ( View Tweet)
#ACR21 Abs#0101 on recombinant #zoster vaccine (RZV) in #IMIDs:
•High proportion of ≥50yos w/ IMIDs received RZV but 15–25% did not get 2nd dose within 6m
•#Vaccination higher in ≥65yos than 50–64yos
•Need better vaccine policy to encourage uptake in pts w/ IMIDs
@RheumNow https://t.co/i5JDJClTyQ
Mrinalini Dey DrMiniDey ( View Tweet)
@jhrheumatology data on ESRD in Lupus Nephritis, Dr. Michelle Petri. #ACR21 Debate
▶️ 20% risk of renal failure in 20 years is way too high
▶️ C3 strongest predictor, dsDNA also seen
⭐️⬇️ complement, ⬆️dsDNA in lupus nephritis suggests Belimumab is good agent for LN
@Rheumnow https://t.co/ewLAxMgTT0
Eric Dein ericdeinmd ( View Tweet)
#ACR21 @RheumNow
Abst#0359 by Garrido-Cumbrera et al. has mapped out the journey from symptom onset to diagnosis of axSpA across 13 European countries.
swethaann23 swethaann23 ( View Tweet)
Before the Great Debate:
Next step for Lupus Nephritis?
#ACR21 @Rheumnow
Eric Dein ericdeinmd ( View Tweet)
Abstract 0095 Barbhiaya et al examined risk factors for 'Long Haul' COVID-19 in Rheumatology Outpatients in NYC #ACR21 @RheumNow
Akhil Sood MD AkhilSoodMD ( View Tweet)
Phase 2 German study demonstrates superiority of TCZ vs PBO in FMF. SAA levels only normalized in TCZ treated patients. Interesting concept that needs to be replicated in larger trials. Abs 0193 #ACR21 #RheumNow @RheumNow https://t.co/awqOpwg3gH https://t.co/lGzYglnkyM
Dr. Rachel Tate uptoTate ( View Tweet)
Abst0242 #ACR21 @RheumNow FROST: 1st line Rx of SJIA 73 pts. two study arms: biologics & GC/MTX arm. In biologic arm 14% IL-1i switched to IL-6i, 0% from IL-6i to IL-1i. 50%GC/MTX eventually initiated biologic therapy . 57% of pts d/cGC use, and 75% had cJADAS-10 score ≤ 2.5 https://t.co/vH0AnocTr2
Olga Petryna DrPetryna ( View Tweet)
Data science for the dumbs. Very informative talk from Dr Jamie Collins! Surely helpful for me. A good way to decide on the best supervised methods for data analysis in machine learning is to separate according to our goal: to explain or to predict? #ACR2021 @RheumNow https://t.co/J0j6VMkoTV
Aurelie Najm AurelieRheumo ( View Tweet)